{rfName}
Th

Indexed in

License and use

Citations

1

Altmetrics

Article has an altmetric score of 47

Analysis of institutional authors

Jane, EAuthor
Share
Publications
>
Article

The Theranostic Genome

Publicated to:Nature Communications. 15 (1): 10904- - 2024-12-30 15(1), DOI: 10.1038/s41467-024-55291-x

Authors: Xu, XY; Jané, P; Taelman, V; Jané, E; Dumont, RA; Garama, Y; Kim, F; Gómez, MD; Gariani, K; Walter, MA

Affiliations

Geneva Univ Hosp, Div Endocrinol Diabet Nutr & Patient Therapeut Edu, Geneva - Author
Geneva Univ Hosp, Nucl Med & Mol Imaging Div, Geneva - Author
Univ Lucerne, Luzern - Author
Univ Lucerne, St Anna Hosp, Luzern - Author
Univ Politecn Madrid, ETSIAE, Dept Matemat Aplicada Ingn Aerosp, Madrid 28040, Spain; Hosp Univ Ramon & Cajal, Serv Med Nucl - Author
See more

Abstract

Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications. Using a deep learning-based hybrid human-AI pipeline that cross-references PubMed, the Gene Expression Omnibus, DisGeNET, The Cancer Genome Atlas and the NIH Molecular Imaging and Contrast Agent Database, we bridge individual genes in human cancers with respective theranostic compounds. Cross-referencing the Theranostic Genome with RNAseq data from over 17'000 human tissues identifies theranostic targets and lead compounds for various human cancers, and allows tailoring targeted theranostics to relevant cancer subpopulations. We expect the Theranostic Genome to facilitate the development of new targeted theranostics to better diagnose, understand, treat, and monitor a variety of human cancers.

Keywords
(he)3 zher3(08698) dotaga in 111AblationAmino acid sequenceAmino acid substitutionArticleArtificial intelligenceBile duct carcinomaBone marrow cellCancerCancer tissueCastration resistant prostate cancerChromophobe renal cell carcinomaChx a'' dtpa dupa pep ga 68Clear cell papillary renal cell carcinomaColon adenocarcinomaControlled studyCyclooctyne dota mmpi ga 68CytoscapeDatabaseDeep learningDisease treatmentDota chce7 lu 177Dota peg antiepcam aptamer cu 64Dota rituximab lu 177Dtpa (anti hcg) in 11Dtpa anti myosin in 111Gene expressionGeneticsGenomeGenome, humanHbed cc azepin metmab ga 68HumansHynic aptedb tc 99mHynic chk tc 99mInvasive breast cancerKnowledge gapLiver cell carcinomaLung adenocarcinomaMaleMalignant neoplasmMedical subject headingsMedicineMedlineMesotheliomaMetastatic castration resistant prostate cancerMolecular imagingNatural killer cellNatural language processingNeoplasmNeoplasmsNota msa ga 68OncogenomicsPancreas adenocarcinomaPapillary renal cell carcinomaParagangliomaPeptidePersonalized cancer therapyPersonalized medicinePetPheochromocytomaPleiotropyPrecision medicinePredictionProceduresProstate adenocarcinomaProstate tissueProteomeRadioiodineRadiotracerReceptorRectal adenocarcinomaRna sequencingSarcomaSquamous cell lung carcinomaStomach adenocarcinomaTesticular germ cell tumorTheranostic nanomedicineTherapyThyroid carcinomaTracerTranscriptomeTransitional cell carcinoma of the bladderUnclassified drugUterine carcinosarcomaUterine cervix cancerUvea melanomaY chromosome

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Nature Communications due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 8/134, thus managing to position itself as a Q1 (Primer Cuartil), in the category Multidisciplinary Sciences. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-05-20:

  • Scopus: 1
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-20:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 16.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 16 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 47.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Switzerland.